Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

Prior treatment

• Had an SAE in Study LP352-201 that was definitely, probably, or possibly related to exposure to study drug
• Currently taking anorectic agents, monoamine oxidase inhibitors; serotonin agonists or antagonists including fenfluramine, atomoxetine, vortioxetine, or other medications for weight loss
• Positive test result on the drug screen, except tetrahydrocannabinol (THC) for patients taking prescribed cannabidiol

Other illness

• Current or past history of cardiovascular or cerebrovascular disease, such as cardiac valvulopathy, myocardial infarction, stroke, pulmonary arterial hypertension or abnormal blood pressure
• Has glaucoma, renal impairment, liver disease or any other medical condition that would affect study participation or pose a risk to the subject
• Current or recent history of moderate or severe depression, anorexia nervosa, bulimia or at risk of suicidal behavior

• Male or non-pregnant, non-lactating female, age 12 to 65 years who have satisfactorily completed study LP352-201
• Diagnosis of Dravet syndrome, Lennox-Gastaut syndrome, or other developmental and epileptic encephalopathy
• The patient/parent/caregiver is able and willing to attend study visits, complete the diary and take study drug as instructed